Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

BACKGROUND: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects. CASE PRESENTATION: We report on effects of dupilumab in a patient with seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Nettis, Eustachio, Masciopinto, Lucia, Di Leo, Elisabetta, De Candia, Nicola, Albanesi, Marcello, Di Bona, Danilo, Quaranta, Nicola, Macchia, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207639/
https://www.ncbi.nlm.nih.gov/pubmed/34134707
http://dx.doi.org/10.1186/s12948-021-00144-x
_version_ 1783708811904679936
author Nettis, Eustachio
Masciopinto, Lucia
Di Leo, Elisabetta
De Candia, Nicola
Albanesi, Marcello
Di Bona, Danilo
Quaranta, Nicola
Macchia, Luigi
author_facet Nettis, Eustachio
Masciopinto, Lucia
Di Leo, Elisabetta
De Candia, Nicola
Albanesi, Marcello
Di Bona, Danilo
Quaranta, Nicola
Macchia, Luigi
author_sort Nettis, Eustachio
collection PubMed
description BACKGROUND: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects. CASE PRESENTATION: We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). CONCLUSIONS: Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.
format Online
Article
Text
id pubmed-8207639
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82076392021-06-16 Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis Nettis, Eustachio Masciopinto, Lucia Di Leo, Elisabetta De Candia, Nicola Albanesi, Marcello Di Bona, Danilo Quaranta, Nicola Macchia, Luigi Clin Mol Allergy Case Report BACKGROUND: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects. CASE PRESENTATION: We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). CONCLUSIONS: Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint. BioMed Central 2021-06-16 /pmc/articles/PMC8207639/ /pubmed/34134707 http://dx.doi.org/10.1186/s12948-021-00144-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Nettis, Eustachio
Masciopinto, Lucia
Di Leo, Elisabetta
De Candia, Nicola
Albanesi, Marcello
Di Bona, Danilo
Quaranta, Nicola
Macchia, Luigi
Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis
title Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis
title_full Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis
title_fullStr Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis
title_full_unstemmed Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis
title_short Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis
title_sort dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207639/
https://www.ncbi.nlm.nih.gov/pubmed/34134707
http://dx.doi.org/10.1186/s12948-021-00144-x
work_keys_str_mv AT nettiseustachio dupilumabelicitsafavorableresponseintype2inflammatorycomorbiditiesofsevereatopicdermatitis
AT masciopintolucia dupilumabelicitsafavorableresponseintype2inflammatorycomorbiditiesofsevereatopicdermatitis
AT dileoelisabetta dupilumabelicitsafavorableresponseintype2inflammatorycomorbiditiesofsevereatopicdermatitis
AT decandianicola dupilumabelicitsafavorableresponseintype2inflammatorycomorbiditiesofsevereatopicdermatitis
AT albanesimarcello dupilumabelicitsafavorableresponseintype2inflammatorycomorbiditiesofsevereatopicdermatitis
AT dibonadanilo dupilumabelicitsafavorableresponseintype2inflammatorycomorbiditiesofsevereatopicdermatitis
AT quarantanicola dupilumabelicitsafavorableresponseintype2inflammatorycomorbiditiesofsevereatopicdermatitis
AT macchialuigi dupilumabelicitsafavorableresponseintype2inflammatorycomorbiditiesofsevereatopicdermatitis

Ejemplares similares